Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.

The ability of dendritic cells (DCs) to cross-present protein tumor antigens to cytotoxic T lymphocytes (CTLs) underpins the success of therapeutic cancer vaccines. We studied cross-presentation of the cancer/testis antigen, NY-ESO-1, and the melanoma differentiation antigen, Melan-A by human DC subsets. Monocyte-derived DCs (MoDCs) efficiently cross-presented human leukocyte associated (HLA)-A2-restricted epitopes from either a formulated NY-ESO-1/ISCOMATRIX vaccine or when either antigen was mixed with ISCOMATRIX adjuvant. HLA-A2 epitope generation required endosomal acidification and was proteasome-independent for NY-ESO-1 and proteasome-dependent for Melan-A. Both MoDCs and CD1c(+) blood DCs cross-presented NY-ESO-1-specific HLA-A2(157-165)-, HLA-B7(60-72)-, and HLA-Cw3(92-100)-restricted epitopes when formulated as an NY-ESO-1/ISCOMATRIX vaccine, but this was limited when NY-ESO-1 and ISCOMATRIX adjuvant were added separately to the DC cultures. Finally, cross-presentation of NY-ESO-1(157-165)/HLA-A2, NY-ESO-1(60-72)/HLA-B7, and NY-ESO-1(92-100)/HLA-Cw3 epitopes was proteasome-dependent when formulated as immune complexes (ICs) but only proteasome-dependent for NY-ESO-1(60-72)/HLA-B7-restricted cross-presentation facilitated by ISCOMATRIX adjuvant. We demonstrate, for the first time, proteasome-dependent and independent cross-presentation of HLA-A-, B-, and C-restricted epitopes within the same full-length tumor antigen by human DCs. Our findings identify important differences in the capacities of human DC subsets to cross-present clinically relevant, full-length tumor antigens and how vaccine formulation impacts CTL responses in vivo.

[1]  E. Maraskovsky,et al.  Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant , 2009, Immunology and cell biology.

[2]  S. Endres,et al.  ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II1 , 2009, The Journal of Immunology.

[3]  Lisa M. Ebert,et al.  A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. , 2009, Cancer research.

[4]  J. Tiercy,et al.  Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients , 2009, Cancer Immunology, Immunotherapy.

[5]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[6]  S. Naik.  Demystifying the development of dendritic cell subtypes, a little , 2008, Immunology and cell biology.

[7]  A. Mowat,et al.  Simultaneous presentation and cross‐presentation of immune‐stimulating complex‐associated cognate antigen by antigen‐specific B cells , 2008, European journal of immunology.

[8]  S. Amigorena,et al.  Phagocytosis and antigen presentation in dendritic cells , 2007, Immunological reviews.

[9]  J. Villadangos,et al.  Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo , 2007, Nature Reviews Immunology.

[10]  A. Belldegrun,et al.  Dendritic Cell Surface Calreticulin Is a Receptor for NY-ESO-1: Direct Interactions between Tumor-Associated Antigen and the Innate Immune System1 , 2006, The Journal of Immunology.

[11]  G. Belz,et al.  The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Belz,et al.  Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity , 2006, Nature Immunology.

[13]  B. Gazzard,et al.  Human BDCA-1-Positive Blood Dendritic Cells Differentiate into Phenotypically Distinct Immature and Mature Populations in the Absence of Exogenous Maturational Stimuli: Differentiation Failure in HIV Infection1 , 2005, The Journal of Immunology.

[14]  J. Derry,et al.  Nectin-like Protein 2 Defines a Subset of T-cell Zone Dendritic Cells and Is a Ligand for Class-I-restricted T-cell-associated Molecule*♦ , 2005, Journal of Biological Chemistry.

[15]  A. Scott,et al.  Recombinant NY‐ESO‐1 Cancer Antigen: Production and Purification under cGMP Conditions , 2005, Preparative biochemistry & biotechnology.

[16]  I. Davis,et al.  Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. , 2005, Blood.

[17]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[18]  Mark Shackleton,et al.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Luft,et al.  NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors , 2004, Clinical Cancer Research.

[20]  A. Mowat,et al.  Dendritic cell maturation enhances CD8+ T‐cell responses to exogenous antigen via a proteasome‐independent mechanism of major histocompatibility complex class I loading , 2003, Immunology.

[21]  K. MacDonald,et al.  Characterization of human blood dendritic cell subsets. , 2002, Blood.

[22]  I. Mellman,et al.  Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Rafiq,et al.  Immune complex-mediated antigen presentation induces tumor immunity. , 2002, The Journal of clinical investigation.

[24]  Antonio Lanzavecchia,et al.  BDCA-2, a Novel Plasmacytoid Dendritic Cell–specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon α/β Induction , 2001, The Journal of experimental medicine.

[25]  A. Macagno,et al.  Pronounced up‐regulation of the PA28α/β proteasome regulator but little increase in the steady‐state content of immunoproteasome during dendritic cell maturation , 2001, European journal of immunology.

[26]  A. Palucka,et al.  Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells , 2000, The Journal of experimental medicine.

[27]  S. Miltenyi,et al.  BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood , 2000, The Journal of Immunology.

[28]  Nina Bhardwaj,et al.  Consequences of cell death: exposure to necrotic tumor cells , 2000 .

[29]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.

[30]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[31]  F. Sallusto,et al.  Dendritic cells up‐regulate immunoproteasomes and the proteasome regulator PA28 during maturation , 1999, European journal of immunology.

[32]  D. Speiser,et al.  High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals , 1999, The Journal of experimental medicine.

[33]  F. Brasseur,et al.  Genes encoding tumor-specific antigens are expressed in human myeloma cells. , 1999, Blood.

[34]  M. Colombo,et al.  Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response , 1999, The Journal of experimental medicine.

[35]  F. Marincola,et al.  Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. , 1998, Journal of immunology.

[36]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[37]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[38]  M. Bevan,et al.  Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. , 1997, Blood.

[39]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Colombo,et al.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.

[41]  M. Lotze,et al.  Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[42]  R. Steinman,et al.  Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.

[43]  J. Peters,et al.  Signals required for differentiating dendritic cells from human monocytes in vitro. , 1993, Advances in experimental medicine and biology.

[44]  R. Steinman,et al.  Dendritic cells are accessory cells for the development of anti- trinitrophenyl cytotoxic T lymphocytes , 1980, The Journal of experimental medicine.

[45]  M. Bevan,et al.  Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. , 1976, Journal of immunology.